Here's a new summary of all the drugs in the pipeline currently being evaluated for the treatments of vasculitis.

Biological drugs have improved the lives of many people with severe asthma. However, a new study from Karolinska Institutet ...

Chart Industries and Flowserve Corporation announced June 4 that they’ve reached a deal to combine in an all-stock “merger of equals”. Upon completion — expected in 2025’s fourth quarter and subject ...

Introduction Inflammatory bowel diseases (IBDs) are chronic diseases of unknown cause characterised by a progressive and unpredictable disease course. In the last decade, biological treatment has ...

It is possible to produce an inflammatory response, using carrageenan, in the peritoneal cavity with predominance of many polymorphonuclear cells present in the exudate. The treatment of the animals ...

The in vivo implanted biomaterials are known to induce inflammatory response and recruit immune cells, which could be used as robust adjuvants for immunotherapy. ... Revealing the compressive and flow ...

The stress-inducible protein heme oxygenase-1 provides protection against oxidative stress. The anti-inflammatory properties of heme oxygenase-1 may serve as a basis for this cytoprotection. We ...

In retrospect, the first-day response from investors does not seem like an overreaction. At Tuesday's close, Chart stock had gained less than 5% from where it finished the day the acquisition was ...

Chart Industries and Flowserve Strike All-Stock Merger. The combined entity will be worth roughly $19 billion, including debt. By . Lauren Thomas. Share. Resize. Listen (1 min) ...

Flowserve Corporation and Chart Industries, Inc. merge for $300M synergies, sparking investor skepticism on growth and strategy. Click for my take on FLS and GTLS.

ATLANTA & DALLAS - Chart Industries, Inc. (NYSE: GTLS) and Flowserve Corporation (NYSE: FLS) have announced their agreement to merge in an all-stock deal, which is expected to create an enterprise ...